Compare Aurobindo Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TORRENT PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA TORRENT PHARMA AUROBINDO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 7.3 42.2 17.3% View Chart
P/BV x 1.8 9.2 19.1% View Chart
Dividend Yield % 0.6 1.1 55.1%  

Financials

 AUROBINDO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-21
TORRENT PHARMA
Mar-21
AUROBINDO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0233,040 33.7%   
Low Rs3331,933 17.2%   
Sales per share (Unadj.) Rs422.8473.0 89.4%  
Earnings per share (Unadj.) Rs92.074.0 124.3%  
Cash flow per share (Unadj.) Rs110.0112.9 97.5%  
Dividends per share (Unadj.) Rs4.0035.00 11.4%  
Avg Dividend yield %0.61.4 41.9%  
Book value per share (Unadj.) Rs374.3344.9 108.5%  
Shares outstanding (eoy) m585.94169.22 346.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.65.3 30.5%   
Avg P/E ratio x7.433.6 21.9%  
P/CF ratio (eoy) x6.222.0 28.0%  
Price / Book Value ratio x1.87.2 25.1%  
Dividend payout %4.347.3 9.2%   
Avg Mkt Cap Rs m397,398420,798 94.4%   
No. of employees `000NANA-   
Total wages/salary Rs m35,35014,396 245.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m247,74680,048 309.5%  
Other income Rs m3,809757 502.9%   
Total revenues Rs m251,55580,806 311.3%   
Gross profit Rs m81,48024,666 330.3%  
Depreciation Rs m10,5546,578 160.4%   
Interest Rs m7453,583 20.8%   
Profit before tax Rs m73,99015,263 484.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m20,0982,744 732.5%   
Profit after tax Rs m53,89212,519 430.5%  
Gross profit margin %32.930.8 106.7%  
Effective tax rate %27.218.0 151.1%   
Net profit margin %21.815.6 139.1%  
BALANCE SHEET DATA
Current assets Rs m198,23555,232 358.9%   
Current liabilities Rs m106,65248,916 218.0%   
Net working cap to sales %37.07.9 468.5%  
Current ratio x1.91.1 164.6%  
Inventory Days Days1914 133.7%  
Debtors Days Days527 743.0%  
Net fixed assets Rs m135,77881,298 167.0%   
Share capital Rs m586846 69.2%   
"Free" reserves Rs m218,71357,526 380.2%   
Net worth Rs m219,29958,372 375.7%   
Long term debt Rs m1,68429,633 5.7%   
Total assets Rs m334,013136,530 244.6%  
Interest coverage x100.35.3 1,907.4%   
Debt to equity ratio x00.5 1.5%  
Sales to assets ratio x0.70.6 126.5%   
Return on assets %16.411.8 138.7%  
Return on equity %24.621.4 114.6%  
Return on capital %33.821.4 157.9%  
Exports to sales %53.80-   
Imports to sales %16.40-   
Exports (fob) Rs m133,248NA-   
Imports (cif) Rs m40,615NA-   
Fx inflow Rs m133,24821,539 618.6%   
Fx outflow Rs m44,9467,136 629.8%   
Net fx Rs m88,30214,403 613.1%   
CASH FLOW
From Operations Rs m33,28920,107 165.6%  
From Investments Rs m5,987-4,494 -133.2%  
From Financial Activity Rs m-13,648-16,561 82.4%  
Net Cashflow Rs m25,831-893 -2,893.9%  

Share Holding

Indian Promoters % 48.8 71.3 68.4%  
Foreign collaborators % 3.1 0.0 -  
Indian inst/Mut Fund % 37.9 20.6 184.1%  
FIIs % 21.4 11.6 183.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.2 28.8 167.5%  
Shareholders   341,568 67,205 508.2%  
Pledged promoter(s) holding % 24.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUN PHARMA    LUPIN    CIPLA    DR. REDDYS LAB    CADILA HEALTHCARE    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Torrent Pharma Beats Expectations: Stock Gets a Boost (Views On News)

May 19, 2021

Key takeaways from Torrent Pharma's March quarter results.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 21, 2022 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - BERYL DRUGS COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS